# Multi-Modal Brain Tumor Segmentation: ML Pipelines Freeze Status & Master Audit

---

## 1. Master Freeze Declaration

Both independent deep learning segmentation pipelines—**Glioma** and **Meningioma**—have completed all training, post-processing optimization, formal evaluation, spatial restoration, and quality control (QC) procedures. 

**Effective Immediately:**
- Both ML pipelines are declared **100% FROZEN**.
- **No model retraining, fine-tuning, or weight modifications are permitted.**
- **No preprocessing transformations, image resampling, or intensity scaling logic may be altered.**
- **No post-processing parameters (probability thresholds $\tau$, connected-component connectivity, minimum component thresholds) may be tuned or modified.**
- All future development is strictly restricted to downstream architectural layers: unified inference orchestration, clinical API services, data contracts, and interactive 3D frontend visualizers.

---

## 2. Frozen Pipelines Master Comparison Table

| Pipeline Dimension | Glioma Segmentation Pipeline | Meningioma Segmentation Pipeline |
| :--- | :--- | :--- |
| **Clinical Target** | Adult Diffuse Glioma (ASNR-MICCAI BraTS GLI) | Meningioma Radiotherapy (BraTS MEN-RT) |
| **Pipeline Status** | **FROZEN** | **FROZEN** |
| **Model Architecture** | MONAI 3D U-Net (4 levels, residual units=2) | MONAI 3D U-Net (4 levels, residual units=2) |
| **Input Channels** | 4 modalities: `[T1, T1c, T2, FLAIR]` | 1 modality: `[T1c]` |
| **Output Classes** | 4 classes: Background (0), NCR/NET (1), ED (2), ET (3) | 2 classes: Background (0), Meningioma GTV (1) |
| **Target Subregions** | WT ($1+2+3$), TC ($1+3$), ET ($3$) | GTV (Gross Tumor Volume) |
| **Checkpoint Path** | `outputs/glioma_training/glioma_best_medium_experiment.pth` | `outputs/meningioma_training/meningioma_best.pth` |
| **Preprocessing** | $1.0\,\text{mm}$ isotropic resampling + percentile scaling $[0, 1]$ | $1.0\,\text{mm}$ isotropic resampling + percentile scaling $[0, 1]$ |
| **Inference Engine** | MONAI sliding-window ($64^3$ ROI, overlap=0.50, Gaussian) | MONAI sliding-window ($64^3$ ROI, overlap=0.50, Gaussian) |
| **Frozen Threshold ($\tau$)** | $\tau = 0.60$ on Whole Tumor prob $P(1)+P(2)+P(3)$ | $\tau = 0.125$ on Meningioma prob $P(1)$ |
| **Frozen CC Filter** | 3D 6-connectivity, remove clusters $< 1000$ voxels | 3D 6-connectivity, remove clusters $< 2500$ voxels |
| **Evaluation Scope** | Formal 20-case full-volume validation cohort | 70-case validation cohort + 100-case dev split |
| **Ground-Truth Masks** | **Available** (Full multi-class expert GTV segmentations) | **Unavailable** in 70-case Val (Competition challenge) |
| **Primary Metric** | **WT Micro Dice: 90.42%** (IoU: 82.52%) | **Geometry Verification: 70/70 PASS (100%)** |
| **QC Verdict** | **PASS WITH DIFFICULT CASES** | **PASS WITH UNCERTAINTY** |
| **Master Documentation** | [`docs/GLIOMA_FINAL_EVALUATION.md`](file:///c:/Users/nchan/Desktop/DL/docs/GLIOMA_FINAL_EVALUATION.md) | [`docs/MENINGIOMA_VALIDATION_QC.md`](file:///c:/Users/nchan/Desktop/DL/docs/MENINGIOMA_VALIDATION_QC.md) |

---

## 3. Glioma Pipeline Frozen Baseline & Formal Evaluation

### 3.1. Technical Baseline
- **Training Cohort**: 100 training cases (deterministic seed 42)
- **Validation Cohort**: 20 complete, independent full-volume cases
- **Inference Mode**: Non-destructive 3D patch sliding window ($64 \times 64 \times 64$, overlap $0.50$, Gaussian blending)
- **Post-Processing**: Threshold $\tau = 0.60$ on aggregate tumor probability + 3D 6-connectivity morphological cluster filter ($<1,000\,\text{voxels}$ discarded, removing $98.0\%$ of spurious FP components)

### 3.2. Formal Full-Volume Metrics (20 Validation Cases)
- **Whole Tumor (WT)**:
  - **Micro Dice**: $\mathbf{0.904232}$ ($90.42\%$)
  - **Micro IoU**: $\mathbf{0.825203}$ ($82.52\%$)
  - **Micro Precision**: $\mathbf{0.906649}$ ($90.66\%$)
  - **Micro Recall**: $\mathbf{0.901828}$ ($90.18\%$)
  - **Macro Dice**: $0.847798 \pm 0.146615$ (Median: $0.901276$)
- **Tumor Core (TC)**:
  - **Micro Dice**: $\mathbf{0.766601}$ ($76.66\%$)
- **Enhancing Tumor (ET)**:
  - **Micro Dice**: $\mathbf{0.840123}$ ($84.01\%$)
- **Volumetric Correlation**:
  - **Pearson $r$**: $\mathbf{0.984216}$
  - **Spearman $\rho$**: $\mathbf{0.977444}$
  - **Coefficient of Determination ($R^2$)**: $\mathbf{0.966613}$
  - **Mean Absolute Error (MAE)**: $6,148.45\,\text{mm}^3$
  - **Mean Relative Error (MRE)**: $15.43\%$

### 3.3. Quality Control (QC) Verdict
- **Verdict**: **PASS WITH DIFFICULT CASES**
- **Analysis**: The pipeline achieves top-tier clinical volume correlation ($R^2 > 0.96$) and high Dice overlap on standard and large tumors. Difficult cases (e.g., `BraTS-GLI-00402-000`, `BraTS-GLI-01080-000`) stem from small tumor volumes ($<35\,\text{cm}^3$) or non-enhancing pathology (GT ET $= 0$). Zero complete detection failures were observed.

---

## 4. Meningioma Pipeline Frozen Baseline & Technical QC

### 4.1. Technical Baseline
- **Training Cohort**: 500 training cases / 100-case development split
- **Validation Cohort**: 70 official unblinded cases (`BraTS2024-MEN-RT-Val-v1`)
- **Input**: Single-channel T1c
- **Inference Mode**: $64 \times 64 \times 64$ sliding window, overlap $0.50$, Gaussian blending
- **Post-Processing**: Threshold $\tau = 0.125$ + 3D 6-connectivity cluster filter ($<2,500\,\text{voxels}$ discarded)
- **Spatial Restoration**: Automated resample-inversion mapping back to native acquisition space

### 4.2. Spatial Restoration & Geometry Verification (70/70 PASS)
All 70 restored validation predictions were evaluated against their raw clinical NIfTI headers:
- **Matrix Dimensions $(X, Y, Z)$**: **70 / 70 PASS (100%)**
- **Voxel Spacing $(\Delta x, \Delta y, \Delta z)$**: **70 / 70 PASS (100%)**
- **Physical Origin $(x_0, y_0, z_0)$**: **70 / 70 PASS (100%)**
- **Direction Cosine Matrix**: **70 / 70 PASS (100%)**

### 4.3. Validation Statistics & Intrinsic Data Limitations
- **Validation Dataset Nature**: The official 70-case validation split contains **NO ground-truth GTV masks**.
- **Prohibited Calculations**: Calculating Dice, IoU, Sensitivity, Specificity, or claiming that positive detection rate ($84.29\%$) equals accuracy is **strictly prohibited**.
- **Detection Summary**: 59 positive cases ($84.29\%$), 11 negative cases ($15.71\%$), mean positive volume $18.75\,\text{cm}^3$.

### 4.4. Quality Control (QC) Verdict
- **Verdict**: **PASS WITH UNCERTAINTY**
- **Analysis**: Technical restoration and anatomical plausibility are fully verified (100% PASS). Uncertainty arises solely from the absence of challenge ground-truth masks and the necessary suppression of small enhancing lesions ($<2.5\,\text{cm}^3$) by the FP cluster filter.

---

## 5. Immutability & Anti-Regression Directives

To maintain absolute scientific reproducibility and audit compliance, the following directives are strictly enforced:

1. **Checkpoint Immutability**:
   - `outputs/glioma_training/glioma_best_medium_experiment.pth` (MD5 / state preserved)
   - `outputs/meningioma_training/meningioma_best.pth` (MD5 / state preserved)
2. **Post-Processing Parameter Freeze**:
   - Glioma: $\tau = 0.60$, $\text{min\_size} = 1000$ voxels.
   - Meningioma: $\tau = 0.125$, $\text{min\_size} = 2500$ voxels.
3. **Metric Integrity**:
   - Glioma formal benchmarks MUST always cite the 20-case full-volume evaluation results ($90.42\%$ WT Micro Dice), not earlier 5-case exploratory metrics ($92.20\%$).
   - Meningioma validation statistics MUST never report Dice/IoU or mischaracterize detection rates as accuracy.
4. **Source Code Segregation**:
   - Existing ML modeling and evaluation scripts under `segmentation/` are frozen and read-only.
   - New integration, API, router, or UI modules must import or invoke these frozen pipelines via standard, isolated interfaces.

---

## 6. Downstream Architectural Roadmap

With both ML pipelines frozen, development progresses to the deployment and integration phases:

```
+-------------------------------------------------------------------------------+
|                             Clinical User / Client                            |
+-------------------------------------------------------------------------------+
                                        |
                                        v
+-------------------------------------------------------------------------------+
|                       Multi-Modal Routing & Inference API                     |
|                                                                               |
|  - Input Modality Validator (Auto-detects T1, T1c, T2, FLAIR vs single T1c)   |
|  - Pathology Selector (Glioma 4-Class Pipeline vs Meningioma GTV Pipeline)   |
|  - Unified Response Schema (WT, TC, ET subregions + GTV volume metrics)       |
+-------------------------------------------------------------------------------+
         |                                                             |
         v                                                             v
+------------------------------------+       +------------------------------------+
|     Glioma Inference Service       |       |    Meningioma Inference Service    |
| - Frozen 4-Channel U-Net Checkpoint|       | - Frozen 1-Channel U-Net Checkpoint|
| - Sliding Window (64^3, ov=0.50)   |       | - Sliding Window (64^3, ov=0.50)   |
| - Frozen Post-Proc (tau=0.60, 1000)|       | - Frozen Post-Proc (tau=0.125,2500)|
| - Subregion Mapping (WT, TC, ET)   |       | - Original Space Inverse Transform |
+------------------------------------+       +------------------------------------+
                                        |
                                        v
+-------------------------------------------------------------------------------+
|                     Interactive 3D Visualizer & Web Dashboard                 |
|                                                                               |
|  - Multi-planar Orthogonal Slice Views (Axial, Coronal, Sagittal)             |
|  - Interactive 3D Rotatable Mesh/Surface Rendering (Marching Cubes + Three.js)|
|  - Volumetric Quantification Dashboard (WT, TC, ET, GTV in cm^3 / mm^3)       |
+-------------------------------------------------------------------------------+
```

### Next Implementation Stages:
1. **Common Result Schema**: Standardized JSON/dataclass interface encapsulating segmentation masks, spatial metadata, and volumetric measurements.
2. **Unified Inference Service**: Orchestrator executing the correct frozen pipeline based on provided MRI modalities and tumor classification.
3. **FastAPI / Python Web Backend**: RESTful endpoints for asynchronous MRI upload, inference dispatch, and mask download.
4. **Interactive 3D Visualization Suite**: WebGL/Three.js 3D surface mesh rendering with real-time rotation, transparency control, and multi-planar cross-sectional overlays.
5. **End-to-End Regression Test Suite**: Automated integration tests verifying frozen pipeline outputs against known baseline tolerances.

---

## 7. Master Audit Sign-Off

- **Audit Completion Date**: 2026-10-08
- **Glioma Pipeline Status**: **FROZEN (PASS WITH DIFFICULT CASES)**
- **Meningioma Pipeline Status**: **FROZEN (PASS WITH UNCERTAINTY)**
- **Audit Conclusion**: Both machine learning pipelines satisfy all technical, geometric, volumetric, and documentation requirements. The project is cleared to advance to system integration and interactive 3D visualization.

